Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04926974 · ClinicalTrials.gov registry record · NA

Community Access Through Remote Eyesight (CARE) Study

A NA study of Low Vision, sponsored by New England College of Optometry.

Completed
Registry status
NA
Development phase
145
Enrollment target
2
Study locations

NCT04926974: Completed NA study of Low Vision, sponsored by New England College of Optometry.

NCT04926974 is a NA study of Low Vision that has completed, run by New England College of Optometry. The registered enrollment target is 145 participants, below the 404-participant average among 8 other Low Vision trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04926974, a NA study of Low Vision, has completed, sponsored by New England College of Optometry.

COMPLETED
Registry status
NA
Development phase
145 participants
Enrollment target
2
Study locations

Study Summary

Study is a randomized clinical trial evaluating the efficacy of novel mobile application technologies (including Seeing AI, Aira, and Supervision+) to improve quality of life in older adults with low vision by expanding community access and providing assistance with activities of daily living. Aira provides real-time remote personal assistance through a sighted Aira agent supplying direct feedback to assist with visual tasks. Seeing AI provides optical character recognition allowing any text to be read aloud, color identification, bar code reading, scene description, and facial recognition based on stored photos. Supervision + allows one to use the phone as a magnifier, providing magnification and contrast enhancement using the camera of the mobile phone. This study seeks to understand the potential of these technologies to improve daily activities, community participation, independence, and self-sufficiency in this group by examining a technological approach, which has not yet undergone rigorous investigation in a diverse population of older adults with visual impairment. Project objectives are to evaluate mobile applications in a wide range of visual disability, categorized into three groups: (1) mild to moderate visual acuity loss, (2) severe to profound visual acuity loss, and (3) legal blindness secondary to visual field loss. Participants are randomized to one of three intervention groups: (1) Supervision+ application, (2) Aira application, or (3) Seeing AI application for a period of 6 months. For the Aira intervention group, participants will be assigned either with 'restricted' access (current open access areas plus 30 minutes/month anywhere), or 'unrestricted' access (700 minutes), for a period of 3 months with a 3 month cross-over period. Participants may elect to continue the study for an additional 3 months during which time they have access to all 3 study mobile applications. Outcome measures include assessment of changes at three, six and nine months

Primary Outcome

The primary outcome measure is the person change score (before and after intervention), from the adaptive Massof Activity Inventory (AI) Questionnaire. The AI has an item bank of 510 items organized into 50 goals and 460 related visually-based tasks. Subscales range from 0 (not important) to 3 (very important). For those goals rated as important, subjects are asked to rate the task difficulty on subscales of 0 (impossible to do without help) to 5 (not difficult). Rasch analysis is employed to es

Conditions Studied

Interventions

  • BEHAVIORAL Low Vision Rehabilitation

Study Locations (2)

California

  • UCLA Stein Eye Institute - Los Angeles

Massachusetts

  • New England College of Optometry - Boston

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2021-06-02
Est. Completion 2023-09-29
Phase NA
New England College of Optometry

2 total trials

What the finished NCT04926974 record still lists

NCT04926974 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 404-participant average among 8 other Low Vision trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Low Vision appearing as the primary indexed condition, and to 1 intervention - of which Low Vision Rehabilitation is the first listed.

NCT04926974 reports a single indexed study location in California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04926974 about?

NCT04926974 is a clinical study titled "Community Access Through Remote Eyesight (CARE) Study". Study is a randomized clinical trial evaluating the efficacy of novel mobile application technologies (including Seeing AI, Aira, and Supervision+) to improve quality of life in older adults with low vision by expanding community access and providing assistance with activities of daily living. Aira ...

What is the current status of trial NCT04926974?

This trial is currently completed. It is a NA study. The enrollment target is 145 participants. The study started on 2021-06-02. Estimated completion is 2023-09-29.

What conditions does trial NCT04926974 study?

This clinical trial studies the following conditions: Low Vision.

What interventions are being tested in trial NCT04926974?

The interventions under investigation include: Low Vision Rehabilitation (BEHAVIORAL).

Who is sponsoring clinical trial NCT04926974?

This trial is sponsored by New England College of Optometry, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04926974 being conducted?

This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Low Vision

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04926974's enrollment target sits among peer trials

145 4th of 8 higher than 5 of 8 other Low Vision trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Low Vision trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02688959 · 145 participants · NA

    Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)

  • NCT03586609 · 145 participants · Phase 2

    Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

  • NCT03767595 · 145 participants · NA

    ProACT Post-Approval Study

  • NCT03808337 · 145 participants · Phase 2

    Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04926974, the US trial registry maintained by the National Library of Medicine. NCT04926974 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.